Your new experience awaits. Try the new design now and help us make it even better

EDITORIAL article

Front. Immunol., 26 August 2025

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1679921

This article is part of the Research TopicStudying the immune microenvironment of liver cancer using artificial intelligenceView all 12 articles

Editorial: Studying the immune microenvironment of liver cancer using artificial intelligence

  • 1Key Laboratory of Biomechanics and Mechanobiology, Ministry of Education, Beijing Advanced Innovation Center for Biomedical Engineering, School of Engineering Medicine, Beihang University, Beijing, China
  • 2Shanghai Medical College, Fudan University, Shanghai, China
  • 3Tianjin Wutong High School, Tianjin, China
  • 4Department of Cell Biology, College of Basic Medical Sciences, Tianjin Medical University, Tianjin, China
  • 5Department of Public Health, International School, Krirk University, Bangkok, Thailand

A significant number of deaths each year can be attributed to liver cancer, which is known for its rapid progression and poor prognosis (1). It has a severe impact on quality of life and continues to present a major global public health challenge.

Liver cancer often renders chemotherapy and radiation ineffective, complicating treatment. The need for more effective treatment options has led to pioneering technologies being investigated, including artificial intelligence (Figure 1).

Figure 1
A robotic doctor with a medical cross examines a liver using a magnifying glass. Nearby, a computer displays cell graphics, and the background includes various stylized cells and bacteria.

Figure 1. Amazing helping hand: Artificial Intelligence in immunological management of liver disease.

Cancer precision medicine aims to ensure treatments work as well as possible for each patient, while also trying to reduce any nasty side effects. Significant progress in oncology has been made by artificial intelligence through high-dimensional datasets and computing/deep learning (2, 3).

Nevertheless, the use of artificial intelligence in medicine is still in its infancy (4). Despite rapid advancements in algorithmic development, significant challenges remain in the areas of clinical data accumulation, data standardization, and quality verification. The accuracy of artificial intelligence in clinical practice still needs to be improved.

The present editorial introduces the compendium of articles that have been published in Frontiers in Immunology: Cancer Immunity and Immunotherapy Research Topic. We hope that this will encourage high-quality research on artificial intelligence in the field of relativity.

Harnessing multi-omics and artificial intelligence: revolutionizing prognosis and treatment in hepatocellular carcinoma by Wang et al. The study gained an understanding of the different types of this cancer, improving prediction and treatment by combining different kinds of data.

Machine learning-driven prediction of immune checkpoint inhibitor responses against cholangiocarcinoma: a bile biopsy perspective by Zhang et al. Research aims to develop models to detect and treat cholangiocarcinoma early.

Preoperative assessment of liver regeneration using T1 mapping and the functional liver imaging score derived from Gd-EOB-DTPA-enhanced magnetic resonance for patient with hepatocellular carcinoma after hepatectomy by Li et al. The author proves that T1 mapping parameters and functional liver imaging score are potential non-invasive indicators of liver regeneration.

Multiomic analysis of lactylation and mitochondria-related genes in hepatocellular carcinoma identified MRPL3 as a new prognostic biomarker by Xing et al. The author demonstrates that MRPL3 is a dependable predictive biomarker in diagnosing and treating hepatocellular carcinoma.

Pinpointing the integration of artificial intelligence in liver cancer immune microenvironment by Bukhari et al. This review covers recent progress in the immune microenvironment of hepatocellular carcinoma using artificial intelligence.

Integrative multi-omics analysis reveals a novel subtype of hepatocellular carcinoma with biological and clinical relevance by Li et al. This study has built an effective model to predict outcomes for patients with this type of cancer and identified new subgroups.

The complex role of immune cells in antigen presentation and regulation of T-cell responses in hepatocellular carcinoma: progress, challenges, and future directions by Ning et al. This review gives the latest information about this field by studying how liver cancer antigen presentation works.

Screening of genes co-associated with osteoporosis and chronic HBV infection based on bioinformatics analysis and machine learning by Yang et al. The study also focuses on diagnosing and treating chronic HBV. New insights have been gained into the relationship between osteoporosis and chronic HBV infection.

Lactylation signature identifies liver fibrosis phenotypes and traces fibrotic progression to hepatocellular carcinoma by Li et al. This research focuses on hepatocellular carcinoma arising from liver fibrosis, particularly lactylation and related immune infiltration.

Causal relationship between immune cell phenotypes and risk of biliary tract cancer: evidence from Mendelian randomization analysis by Hu et al. Mendelian randomization was employed in this study to explore the potential association between immune cell phenotypes and biliary tract cancer.

Hepatitis B-related hepatocellular carcinoma: classification and prognostic model based on programmed cell death genes by Tian et al. This study used various bioinformatics techniques to analyze RNA sequencing data from patients with Hepatitis B - hepatocellular carcinoma. A prognostic model was also developed, based on genomic and clinical information.

Author contributions

DZ: Writing – original draft. JC: Writing – original draft. BrY: Visualization, Writing – original draft. BY: Supervision, Writing – original draft, Writing – review & editing.

Acknowledgments

The authors would like to express their gratitude to the coeditors of this Research Topic and the contribution of the reviewers.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Wang L, Qiu M, Wu L, Li Z, Meng X, He L, et al. Construction and validation of prognostic signature for hepatocellular carcinoma basing on hepatitis B virus related specific genes. Infect Agents Cancer. (2022) 17:60. doi: 10.1186/s13027-022-00470-y

PubMed Abstract | Crossref Full Text | Google Scholar

2. Chokkakula S, Chong S, Yang B, Jiang H, Yu J, Han R, et al. Quantum leap in medical mentorship: exploring ChatGPT’s transition from textbooks to terabytes. Front Med. (2025) 12:1517981. doi: 10.3389/fmed.2025.1517981

PubMed Abstract | Crossref Full Text | Google Scholar

3. Wu L-l, Yang B, Meng X, Fan G, and Yang B. Artificial intelligence: new hope for critically ill cardiovascular patients. Front Med. (2024) 11:1453169. doi: 10.3389/fmed.2024.1453169

PubMed Abstract | Crossref Full Text | Google Scholar

4. Xianyu Z, Correia C, Yong Ung C, Zhu S, Billadeau DD, and Li H. The rise of hypothesis-driven artificial intelligence in oncology. Cancers. (2024) 16:822. doi: 10.3390/cancers16040822

PubMed Abstract | Crossref Full Text | Google Scholar

Keywords: artificial intelligence - AI, liver disease, immunotherapy, hepatocellular carcinoma, cancer immune microenvironment, cancer precision medicine

Citation: Zhang D-k, Chen J-l, Yang B-r and Yang B (2025) Editorial: Studying the immune microenvironment of liver cancer using artificial intelligence. Front. Immunol. 16:1679921. doi: 10.3389/fimmu.2025.1679921

Received: 05 August 2025; Accepted: 11 August 2025;
Published: 26 August 2025.

Edited and reviewed by:

Peter Brossart, University of Bonn, Germany

Copyright © 2025 Zhang, Chen, Yang and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Bing Yang, YmluZ3lhbmdAdG11LmVkdS5jbg==; eWFuZy5iaW5nQGtyaXJrLmFjLnRo

ORCID: Bing Yang, orcid.org/0000-0002-0408-4518

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.